Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer

European Journal of Cancer

Volumn 49, Issue 10, 2013, Pages 2441-2448

  Gannon, Philippe O ^a   Lessard, Laurent ^a   Stevens, Louis Mathieu ^a   Forest, Valérie ^a   Bégin, Louis R ^b   Minner, Sarah ^c   Tennstedt, Pierre ^c   Schlomm, Thorsten ^c   Mes Masson, Anne Marie ^a,d   Saad, Fred ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biochemical recurrence; Biological marker; Immunohistochemistry; Nuclear factor kappa B (NF B)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SEMINAL VESICLE; TISSUE MICROARRAY; TUMOR INVASION; VALIDATION STUDY;

AGED; CELL NUCLEUS; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEMINAL VESICLES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR RELA; TUMOR MARKERS, BIOLOGICAL;

EID: 84878378906     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.026     Document Type: Article

References (28)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. A.J. Stephenson, P.T. Scardino, and J.A. Eastham Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 28 2005 7005 7012
3. A. Oeckinghaus, M.S. Hayden, and S. Ghosh Crosstalk in NF-kappaB signaling pathways Nat Immunol 12 8 2011 695 708
4. Y. Ben-Neriah, and M. Karin Inflammation meets cancer, with NF-kappaB as the matchmaker Nat Immunol 12 8 2011 715 723
5. L. Lessard, A.M. Mes-Masson, L. Lamarre, L. Wall, J.B. Lattouf, and F. Saad NF-kappa B nuclear localization and its prognostic significance in prostate cancer BJU Int 91 4 2003 417 420
6. H.A. Ismail, L. Lessard, A.M. Mes-Masson, and F. Saad Expression of NF-kappaB in prostate cancer lymph node metastases Prostate 58 3 2004 308 313
7. L. Lessard, P.I. Karakiewicz, and P. Bellon-Gagnon Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases Clin Cancer Res 12 19 2006 5741 5745
8. V. Fradet, L. Lessard, L.R. Begin, P. Karakiewicz, A.M. Masson, and F. Saad Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer Clin Cancer Res 10 24 2004 8460 8464
9. I.H. Koumakpayi, C. Le Page, A.M. Mes-Masson, and F. Saad Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF- kappaB signalling pathway and prognostic significance in prostate cancer Br J Cancer 102 7 2010 1163 1173
10. Q. Zhang, B.T. Helfand, and T.L. Jang Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy Clin Cancer Res 15 10 2009 3557 3567
11. J.S. Ross, B.V. Kallakury, and C.E. Sheehan Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence Clin Cancer Res 10 7 2004 2466 2472
12. J. Domingo-Domenech, B. Mellado, and B. Ferrer Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse Br J Cancer 93 11 2005 1285 1294
13. G.E. Ayala, H. Dai, and M. Ittmann Growth and survival mechanisms associated with perineural invasion in prostate cancer Cancer Res 64 17 2004 6082 6090
14. T. Schlomm, L. Iwers, and P. Kirstein Clinical significance of p53 alterations in surgically treated prostate cancers Mod Pathol 21 11 2008 1371 1378
15. S. Minner, C. Wittmer, and M. Graefen High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer Prostate 2011
16. T. Schlomm, P. Kirstein, and L. Iwers Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer Clin Cancer Res 13 22 Pt 1 2007 6579 6584
17. G.P. Swanson, C. Yu, M.W. Kattan, and M.R. Hermans Validation of postoperative nomograms in prostate cancer patients with long-term follow-up Urology 78 1 2011 105 109
18. S. Shukla, G.T. MacLennan, and P. Fu Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression Neoplasia 6 4 2004 390 400
19. C. Sweeney, L. Li, and R. Shanmugam Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate Clin Cancer Res 10 16 2004 5501 5507
20. C. Nunez, J.R. Cansino, and F. Bethencourt TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma) Histopathology 53 2 2008 166 176
21. E. Jacque, T. Tchenio, G. Piton, P.H. Romeo, and V. Baud RelA repression of RelB activity induces selective gene activation downstream of TNF receptors Proc Natl Acad Sci U S A 102 41 2005 14635 14640
22. N. Nadiminty, J.Y. Chun, W. Lou, X. Lin, and A.C. Gao NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation Prostate 68 16 2008 1725 1733
23. M.M. Shen, and C. Abate-Shen Molecular genetics of prostate cancer: new prospects for old challenges Genes Dev 24 18 2010 1967 2000
24. R.J. Jin, Y. Lho, L. Connelly, Y. Wang, and X. Yu Saint Jean L, et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth Cancer Res 68 16 2008 6762 6769
25. J. Min, A. Zaslavsky, and G. Fedele An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB Nat Med 16 3 2010 286 294
26. D. Chen, M. Frezza, S. Schmitt, J. Kanwar, and Q.P. Dou Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives Curr Cancer Drug Targets 2011
27. M.J. Morris, W.K. Kelly, and S. Slovin A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer J Urol 178 6 2007 2378 2383 [discussion 2383-4]
28. V. Baud, and M. Karin Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls Nat Rev Drug Discov 8 1 2009 33 40